<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046435</url>
  </required_header>
  <id_info>
    <org_study_id>FONDECYT 1061070</org_study_id>
    <nct_id>NCT01046435</nct_id>
  </id_info>
  <brief_title>Effects of Periodontal Therapy on Systemic Inflammation</brief_title>
  <official_title>Effects of Periodontal Therapy on Markers of Systemic Inflammation in Subjects at Cardiovascular Disease Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treating periodontal infections (gum disease)
      will reduce markers of systemic inflammation in patients at risk of cardiovascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims: To determine the effects of periodontal treatment on systemic markers of inflammation
      in subjects with risk of coronary heart disease.

      Methods: The current study is a randomized, double blind clinical trial, with two treatment
      groups.

      Eligible participants will be allocated by restricted randomization using the minimization
      method to the treatment group or to the control group. The treatment group will receive
      periodontal therapy consisting of instructions of plaque control, supra and subgingival
      scaling and root planing, oral systemic metronidazole (250 mg) plus amoxicillin (500 mg) tid
      for 7 days. The control group will receive plaque control instructions, supragingival scaling
      and two placebos. The study plan to enroll 160 participants, 80 in ech arm, over a 6-month
      period. Follow-up clinic visits will be scheduled to occur every 3 months after finishing
      treatment. Baseline and follow-up clinic visits will include periodontal examination, blood
      collection and medical and dental histories. The following biochemical markers will be
      determined at baseline and at 3, 6, 9 and 12 months posttherapy: total, LDL and HDL
      lipoprotein cholesterol and triglycerides, glycemia, high sensitivity C-reactive protein,
      fibrinogen, erythrocyte sedimentation rate and white blood cells count. In diabetic patients,
      glycosylated hemoglobin will be also assessed.

      The study will be conducted in a public health center in Santiago, Chile. To be eligible for
      the study, participants have to be older than 35 years and fulfill the medical and
      periodontal criteria. For the medical criteria participants have to have dyslipidemia, and at
      least one of the following coronary heart disease risk factors: obesity, smoking, diabetes,
      hypertension.

      The periodontal inclusion criteria are: no history of periodontal treatment, the presence of
      at least 14 natural teeth, with at least 4 teeth with interproximal sites with probing depth
      equal or higher than 4 mm and concomitant attachment loss equal or higher than 3 mm, and &gt;30
      % of sites with bleeding on probing.

      The outcomes measures will be levels of serum C-reactive protein, fibrinogen,
      erythrosedimentation rate, white blood cell count.The outcomes will be measured at 0, 3,6,9,
      and 6 months after periodontal therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum levels of C-reactive protein, fibrinogen,erythrosedimentation rate and white blood cell count</measure>
    <time_frame>0, 3, 6, 9 and 12 months after therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical periodontal parameters: probing depth, bleeding on probing, clinical attachment level</measure>
    <time_frame>0, 3, 6, 9 and 12 months after therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Periodontal Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Supragingival scaling plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Plaque control instructions, supra gingival scaling and two placebos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Root planing plus antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>metronidazole and amoxicillin</intervention_name>
    <description>Metronidazole 250 mg three times a day per 7 days</description>
    <arm_group_label>Supragingival scaling plus placebo</arm_group_label>
    <arm_group_label>Root planing plus antibiotics</arm_group_label>
    <other_name>Non-surgical periodontal therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Two placebos</intervention_name>
    <description>Two placebos 3 times a day for 7 days</description>
    <arm_group_label>Supragingival scaling plus placebo</arm_group_label>
    <arm_group_label>Root planing plus antibiotics</arm_group_label>
    <other_name>Community periodontal treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosis of marginal periodontitis

          -  No history of periodontal treatment

          -  At least 14 natural teeth present

          -  Dyslipidemia

          -  And at least one of the following factors:

               -  obesity

               -  diabetes

               -  smoking, hypertension

        Exclusion Criteria:

          -  Rheumatoid arthritis

          -  Any type of cancer in the previous 2 years

          -  Pregnancy and lactation

          -  Indication of the use of antibiotic for invasive procedures

          -  Use of antibiotics in previous three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nestor J. Lopez, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Quintero, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carola Ibieta, DDS</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Y Valenzuela, DMS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lilian Jara, MsB, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelo Llancaqueo, DMS</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dra Eloisa DÃ­az Health Center, Metropolitan Northen Health Service</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <link>
    <url>http://www.fondecyt.cl/578/channel.html</url>
  </link>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>March 24, 2010</last_update_submitted>
  <last_update_submitted_qc>March 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Nestor J. Lopez</name_title>
    <organization>University of Chile Faculty of Dentistry</organization>
  </responsible_party>
  <keyword>periodontitis</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

